AFT Pharmaceuticals Past Earnings Performance
Past criteria checks 5/6
AFT Pharmaceuticals has been growing earnings at an average annual rate of 20.3%, while the Pharmaceuticals industry saw earnings growing at 24.6% annually. Revenues have been growing at an average rate of 15.5% per year. AFT Pharmaceuticals's return on equity is 17.8%, and it has net margins of 8%.
Key information
20.3%
Earnings growth rate
20.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.6% |
| Revenue growth rate | 15.5% |
| Return on equity | 17.8% |
| Net Margin | 8.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
May 25
Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?
May 22Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?
Oct 17Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?
May 23Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?
Dec 01We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise
Jul 30With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For
Jun 02Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?
Mar 20A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation
Feb 13
Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 23Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?
Jan 02Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?
Dec 12AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 21Revenue & Expenses Breakdown
How AFT Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 195 | 16 | 56 | 8 |
| 31 Dec 23 | 185 | 13 | 55 | 7 |
| 30 Sep 23 | 175 | 11 | 56 | 5 |
| 30 Jun 23 | 166 | 11 | 53 | 4 |
| 31 Mar 23 | 157 | 11 | 49 | 4 |
| 31 Dec 22 | 149 | 14 | 46 | 4 |
| 30 Sep 22 | 141 | 17 | 42 | 4 |
| 30 Jun 22 | 135 | 18 | 40 | 4 |
| 31 Mar 22 | 130 | 20 | 38 | 4 |
| 31 Dec 21 | 125 | 15 | 38 | 3 |
| 30 Sep 21 | 120 | 11 | 39 | 3 |
| 30 Jun 21 | 116 | 9 | 38 | 2 |
| 31 Mar 21 | 113 | 8 | 37 | 2 |
| 31 Dec 20 | 110 | 5 | 36 | 1 |
| 30 Sep 20 | 107 | 3 | 36 | 0 |
| 30 Jun 20 | 107 | 7 | 37 | 0 |
| 31 Mar 20 | 106 | 12 | 37 | 0 |
| 31 Dec 19 | 100 | 11 | 36 | 0 |
| 30 Sep 19 | 94 | 11 | 35 | 1 |
| 30 Jun 19 | 89 | 4 | 35 | 1 |
| 31 Mar 19 | 85 | -3 | 35 | 1 |
| 31 Dec 18 | 84 | -7 | 38 | 2 |
| 30 Sep 18 | 83 | -11 | 40 | 4 |
| 30 Jun 18 | 82 | -12 | 39 | 5 |
| 31 Mar 18 | 81 | -14 | 39 | 7 |
| 31 Dec 17 | 79 | -14 | 37 | 8 |
| 30 Sep 17 | 76 | -14 | 34 | 10 |
| 30 Jun 17 | 73 | -16 | 34 | 10 |
| 31 Mar 17 | 69 | -18 | 34 | 9 |
| 31 Dec 16 | 67 | -18 | 33 | 8 |
| 30 Sep 16 | 64 | -18 | 32 | 8 |
| 30 Jun 16 | 64 | -16 | 30 | 7 |
| 31 Mar 16 | 64 | -13 | 29 | 6 |
| 31 Dec 15 | 63 | -13 | 27 | 5 |
| 30 Sep 15 | 62 | -13 | 26 | 4 |
| 30 Jun 15 | 59 | -13 | 25 | 4 |
| 31 Mar 15 | 56 | -13 | 24 | 5 |
| 31 Mar 14 | 49 | -1 | 16 | 2 |
Quality Earnings: AFT has high quality earnings.
Growing Profit Margin: AFT's current net profit margins (8%) are higher than last year (6.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AFT has become profitable over the past 5 years, growing earnings by 20.3% per year.
Accelerating Growth: AFT's earnings growth over the past year (46.5%) exceeds its 5-year average (20.3% per year).
Earnings vs Industry: AFT earnings growth over the past year (46.5%) exceeded the Pharmaceuticals industry 22.1%.
Return on Equity
High ROE: AFT's Return on Equity (17.8%) is considered low.